US Federal

FDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications

The FDA is requesting that drug manufacturers remove the warning about suicidal ideation and behavior from the labeling of GLP-1 RA medications approved for weight reduction. This action follows a comprehensive review that found no increased risk associated with these drugs.

FINRA Interpretive Letters on Rule Application

FINRA has published interpretive letters providing guidance on the application of specific FINRA rules under various circumstances. These letters clarify staff views on rules related to communications with the public, account transfers, and registration categories.

FINRA FAQs on Compliance, Advertising, AML, and Trade Reporting

FINRA has published a collection of Frequently Asked Questions (FAQs) covering various compliance topics, including customer assistance in investigations, 529 Savings Plans, accounts at other broker-dealers, advertising, alternative display facilities, anti-money laundering, arbitration, blue sheets, books and records, breakpoints, broker-dealer registration, recruitment disclosures, BrokerCheck, business continuity planning, and CRD.

FINRA Exemptive Letters List

FINRA has published a list of its exemptive letters, including those related to TRACE ATS Reporting, Municipal Securities, and Initial Public Offerings (IPOs). These letters provide guidance to industry professionals on FINRA's decision-making rationale for specific situations.

FINRA Proposes New Trade Reporting Facility Fees Rule

FINRA has proposed a new rule, FINRA Rule 7660B, to establish fees for FINRA members who do not use the FINRA/NYSE Trade Reporting Facility but purchase specified services. This proposal is open for public comment.

FINRA proposes rule changes for underwriting and private placements

FINRA has proposed rule changes to amend Rules 5110 and 5123 concerning underwriting terms and private placements. The proposed changes aim to clarify valuation methods for underwriting compensation, introduce new exemptions, and expand existing exemptions for certain investors.

FINRA Proposes New Outside Activities Rule, Deletes Old Ones

FINRA has filed a proposed rule change with the SEC to adopt a new Rule 3290 concerning outside activities requirements for registered persons and to delete existing Rules 3270 and 3280. The proposed changes aim to enhance member review of activities with heightened risks while reducing unnecessary burdens.

FINRA Proposes Intraday Margin Standards Replacing Day Trading Rules

FINRA has proposed a rule change to replace its current day trading margin provisions with intraday margin standards. This proposal, SR-FINRA-2025-017, would amend FINRA Rule 4210 and eliminate existing day trading margin requirements. The SEC is currently reviewing the proposal.

FINRA proposes rule change on bona fide market making exception

FINRA has proposed a rule change (SR-FINRA-2025-016) to amend FINRA Rule 6830 concerning data reporting under the Consolidated Audit Trail (CAT). The change aims to align reporting requirements with amendments to the CAT NMS Plan regarding the bona fide market making exception under SEC Regulation SHO.

FINRA Amends Annual Reports Extension Policy

FINRA has amended its Annual Reports Extension of Time Request Policy, updating the information required from firms and their auditors. The updated policy, effective December 29, 2025, streamlines the extension process by modifying auditor representation requirements and shifting certain representations to the firm's Principal Financial Officer.